141 related articles for article (PubMed ID: 12801741)
1. Gynaecomastia in men with chronic myeloid leukaemia after imatinib.
Gambacorti-Passerini C; Tornaghi L; Cavagnini F; Rossi P; Pecori-Giraldi F; Mariani L; Cambiaghi N; Pogliani E; Corneo G; Gnessi L
Lancet; 2003 Jun; 361(9373):1954-6. PubMed ID: 12801741
[TBL] [Abstract][Full Text] [Related]
2. Imatinib for chronic myeloid leukaemia: a NICE mess.
Lim D; Muir J
Lancet; 2001 Dec; 358(9296):1903. PubMed ID: 11741656
[No Abstract] [Full Text] [Related]
3. Bilateral masculine mastoplasia associated with imatinib mesylate: a case report and literature review.
Zhao D; Wang G; Li C; Meng L
J Huazhong Univ Sci Technolog Med Sci; 2011 Feb; 31(1):145-146. PubMed ID: 21336741
[No Abstract] [Full Text] [Related]
4. Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.
Campione E; Diluvio L; Paternò EJ; Di Marcantonio D; Francesconi A; Terrinoni A; Orlandi A; Chimenti S
Clin Ther; 2009 Nov; 31(11):2565-9. PubMed ID: 20110001
[TBL] [Abstract][Full Text] [Related]
5. [Molecular mechanism of imatinib-induced thrombocytopenia in treatment of patients with CML].
Shu LL; Jiang QL; Meng FY; Yang M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1314-8. PubMed ID: 22040995
[TBL] [Abstract][Full Text] [Related]
6. [Fulminating hepatitis for imatinib in a patient with chronic myeloid leukaemia].
Martínez Pascual C; Valdés Mas M; de la Peña Moral JM; Miras López M
Med Clin (Barc); 2011 Sep; 137(7):329-30. PubMed ID: 21074222
[No Abstract] [Full Text] [Related]
7. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
8. Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty.
Mariani S; Giona F; Basciani S; Brama M; Gnessi L
Lancet; 2008 Jul; 372(9633):111-112. PubMed ID: 18620939
[No Abstract] [Full Text] [Related]
9. Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate.
Garipidou V; Vakalopoulou S; Tziomalos K
Oncologist; 2005; 10(6):457-8. PubMed ID: 15967839
[No Abstract] [Full Text] [Related]
10. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate.
Schoch C; Haferlach T; Kern W; Schnittger S; Berger U; Hehlmann R; Hiddemann W; Hochhaus A
Leukemia; 2003 Feb; 17(2):461-3. PubMed ID: 12592348
[No Abstract] [Full Text] [Related]
11. Bilateral cystoid macular edema in a patient with chronic myeloid leukaemia under treatment with imanitib mesylate: report of an unusual side effect.
Georgalas I; Pavesio C; Ezra E
Graefes Arch Clin Exp Ophthalmol; 2007 Oct; 245(10):1585-6. PubMed ID: 17562067
[No Abstract] [Full Text] [Related]
12. A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib.
Estabragh ZR; Knight K; Watmough SJ; Lane S; Vinjamuri S; Hart G; Clark RE
Leuk Res; 2011 Jan; 35(1):49-51. PubMed ID: 21030079
[TBL] [Abstract][Full Text] [Related]
13. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.
Santachiara R; Maffei R; Martinelli S; Arcari A; Piacentini F; Trabacchi E; Alfieri P; Ferrari A; Leonardi G; Luppi G; Longo G; Vallisa D; Marasca R; Torelli G
Haematologica; 2008 Aug; 93(8):1252-5. PubMed ID: 18519520
[TBL] [Abstract][Full Text] [Related]
14. STI-571 (Gleevec) in the treatment of chronic myeloid leukaemia.
Kumar L; Kumari M; Menon H
Natl Med J India; 2002; 15(5):298. PubMed ID: 12502149
[No Abstract] [Full Text] [Related]
15. Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation.
Thierry A; Dreyfus B; Bridoux F; Abou Ayache R; Milin S; Guilhot F; Touchard G
Nephrol Dial Transplant; 2007 Jun; 22(6):1791-2. PubMed ID: 17308316
[No Abstract] [Full Text] [Related]
16. Are there new clinical parameters useful to predict response in chronic myeloid leukemia in the imatinib era?
Breccia M; Alimena G
Leuk Res; 2009 Nov; 33(11):1450-1. PubMed ID: 19615745
[No Abstract] [Full Text] [Related]
17. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
Druker BJ; Guilhot F; O'Brien SG; Gathmann I; Kantarjian H; Gattermann N; Deininger MW; Silver RT; Goldman JM; Stone RM; Cervantes F; Hochhaus A; Powell BL; Gabrilove JL; Rousselot P; Reiffers J; Cornelissen JJ; Hughes T; Agis H; Fischer T; Verhoef G; Shepherd J; Saglio G; Gratwohl A; Nielsen JL; Radich JP; Simonsson B; Taylor K; Baccarani M; So C; Letvak L; Larson RA;
N Engl J Med; 2006 Dec; 355(23):2408-17. PubMed ID: 17151364
[TBL] [Abstract][Full Text] [Related]
18. [Management of chronic myeloid leukemia by imatinib].
Kizaki M
Rinsho Ketsueki; 2010 Oct; 51(10):1377-85. PubMed ID: 20962470
[No Abstract] [Full Text] [Related]
19. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
Pawarode A; Sait SN; Nganga A; Coignet LJ; Barcos M; Baer MR
Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756
[TBL] [Abstract][Full Text] [Related]
20. Periungual pyogenic granuloma following imatinib therapy in a patient with chronic myelogenous leukemia.
Dika E; Barisani A; Vaccari S; Fanti PA; Ismaili A; Patrizi A
J Drugs Dermatol; 2013 May; 12(5):512-3. PubMed ID: 23652942
[No Abstract] [Full Text] [Related]
[Next] [New Search]
